3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Meningioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Glioblastoma
1
Estrogen Receptor Positive Breast Cancer
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
282
Rituximab
260
Etoposide
161
Filgrastim
155
Vincristine
145
Doxorubicin
134
Prednisone
117
Cytarabine
108
Radiotherapy
102
Peripheral Blood Stem Cell Transplantation
90
Methotrexate
90
fludarabine phosphate
87
Melphalan
78
Busulfan
71
Dexamethasone
59
Granulocyte Colony-Stimulating Factor
56
Carmustine
53
fludarabine
51
Bortezomib
46
Tacrolimus
44
Mycophenolic Acid
41
Antilymphocyte Serum
41
Ifosfamide
40
Leucovorin
39
Gemcitabine
38
Whole-Body Irradiation
36
Cyclosporine
35
Bendamustine Hydrochloride
34
sargramostim
33
Methylprednisolone
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma
×
vistusertib
×
Clear all
NCT02752204
2020-11-05
TORCH
University of Birmingham
Phase 2
Completed
36 enrolled